A landmark clinical trial involving more than 14,000 patients across 28 countries has found that a novel combination of two widely available drug classes, given together in a once-daily fixed-dose formulation, reduced the rate of major adverse cardiac events -- including heart attacks and cardiovascular deaths -- by 46% compared to standard care alone in patients considered at elevated risk. The results, published Thursday in a leading medical journal and presented simultaneously at a major cardiology conference, are being described by researchers as among the most significant advances in preventive cardiovascular medicine in the past decade.
The trial enrolled patients who had experienced at least one previous cardiovascular event and had at least two additional risk factors, a population for whom current standard-of-care medications have left a substantial residual risk that cardiologists have long sought to reduce. The two drug classes combined in the trial work through complementary mechanisms -- one targeting cholesterol metabolism and the other reducing inflammatory processes that contribute to plaque formation and rupture -- and the combination appears to produce effects that are greater than either drug alone would predict.
The study's principal investigator said the magnitude of the risk reduction surprised even the research team. "We expected a meaningful result -- the mechanistic rationale for this combination was strong," she said. "But a 46% reduction in major events, sustained over a median follow-up of nearly four years, is a number that changes how we think about the pharmacological ceiling for risk reduction in this patient population." The trial's data safety monitoring board recommended stopping enrollment early because the benefit was so clear that it would have been ethically problematic to continue withholding the treatment from control group patients.
“A 46% reduction in major events, sustained over nearly four years, is a number that changes how we think about the pharmacological ceiling for risk reduction in this patient population.”
— Trial principal investigator
The fixed-dose combination tablet used in the trial contains two drugs that are already approved and available generically in most countries, which researchers said should significantly accelerate the path to regulatory approval for the combination product and facilitate rapid adoption in clinical practice. The investigational combination has been submitted for review to regulatory agencies in the United States, European Union, and several other jurisdictions, with decisions expected within 12 months under expedited review procedures that apply to treatments demonstrating substantial improvements over existing therapies.
Cardiology professional societies indicated Thursday that they expect to update clinical guidelines to reflect the trial results within six months, a relatively fast timeline that reflects the strength of the evidence. Health economists who reviewed the trial data estimated that widespread adoption of the treatment among eligible patients could prevent tens of thousands of heart attacks and cardiovascular deaths annually in the United States alone -- and potentially hundreds of thousands globally if access can be achieved in lower-income settings where cardiovascular disease carries a disproportionate burden.